Oxford Nanopore Technologies plc (OXFYY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Oxford Nanopore CEO Francis Van Parys said first-half 2026 performance was reasonably solid, but revenue faced pressure from ongoing headwinds in the Middle East and China. The company does not expect those regional challenges to resolve immediately, although management said it has good visibility toward achieving its full-year objectives. The remarks indicate a cautiously maintained outlook rather than a material change in guidance.

Analysis

The investable issue is not the near-term revenue softness itself, but whether regional disruption exposes a more persistent utilization problem in Oxford Nanopore's installed base. Consumables carry the highest incremental gross-margin contribution; therefore even modest delays in China and Middle East ordering can create disproportionate pressure on gross margin and the path to operating leverage. This favors scaled incumbents such as ILMN and QGEN in procurement-constrained accounts, where service coverage, validated workflows and distributor inventory matter more than platform differentiation.

Management's confidence in the full-year outcome is not independently sufficient to underwrite estimates without evidence of consumables pull-through, instrument placements and backlog conversion by geography. The next 1-3 month catalyst is whether the company quantifies regional revenue exposure or revises implied second-half growth; a guidance hold without improved order visibility would likely be treated as credibility risk. Over 6-18 months, sustained China weakness would raise the required growth rate elsewhere and could force more commercial spending, delaying the operating break-even narrative and limiting multiple expansion.

Consensus may be too focused on headline geographic weakness and too little on competitive substitution: disrupted grant-funded or centralized lab budgets can defer purchases rather than permanently shift them. A recovery in Chinese academic/research tender activity could produce an outsized rebound because consumable reorders have short lead times. Conversely, a sequential decline in flow-cell consumption, lower gross margin, or any reduction in full-year guidance would falsify the rebound case quickly.

ONT's ADR/liquidity profile makes conference-driven price action less reliable than a fundamental signal. Morgan Stanley's conference hosting has no direct earnings implication for MS; the actionable read-through is confined to sequencing and life-science-tools demand.

Key Decisions for Investors

• Maintain no new outright ONT position until the next trading update provides geographic revenue, consumables growth and gross-margin evidence; treat a guidance reiteration without those KPIs as neutral-to-negative rather than a buy signal.
• For existing ONT exposure, reduce risk into any conference-related strength and retain only a small tactical position through the next update. Re-add only if consumables return to sequential growth and management confirms that regional headwinds are not requiring incremental commercial spend; downside trigger is a full-year revenue or margin guide cut.
• Express a 3-6 month defensive relative-value view via long ILMN versus short ONT, sized modestly for ONT liquidity. The thesis is that procurement disruption rewards installed-base scale and validated clinical workflows; exit if ONT demonstrates accelerating consumables growth while ILMN's core consumables trajectory deteriorates.
• Set a China research-spending/tender alert rather than pre-positioning for a rebound. Evidence of resumed tender awards or distributor restocking would be the catalyst to close the ILMN/ONT relative short and consider a tactical ONT long, but the missing exposure and backlog data currently prevent a quantified risk/reward.